Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis
- PMID: 37094084
- DOI: 10.1093/bjd/ljad068
Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis
Conflict of interest statement
Conflicts of interest B.W.M.A. is a patient with atopic dermatitis (AD), an AD advocate, and Patient Associate Editor of the British Journal of Dermatology. He declares no conflicts of interest.
Comment on
-
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022. Br J Dermatol. 2023. PMID: 36994947 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources